temozolomide has been researched along with Meningeal Neoplasms in 40 studies
Meningeal Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on our findings in two paediatric patients, temozolomide may be a useful agent in the management of progressive recurrent low grade spinal cord astrocytomas." | 9.12 | Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. ( Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF, 2006) |
| "A prospective Phase II study of temozolomide (TMZ) was conducted in 16 patients with refractory meningioma." | 9.11 | Temozolomide for treatment-resistant recurrent meningioma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2004) |
| "Temozolomide (TMZ) is a DNA alkylating agent that appears to have a radiosensitizing effect when used in combination with RT and may be worthwhile in meningioma treatment." | 5.72 | Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review. ( Belanger, K; Damek, D; Lillehei, KO; Ormond, DR; Ung, TH, 2022) |
| "High-grade meningioma is an aggressive type of brain cancer that is often recalcitrant to surgery and radiotherapy, leading to poor overall survival." | 5.62 | Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients. ( Basuli, F; Berry, MR; Botham, RC; Chen, Z; Daniel, GB; Fan, TM; Hergenrother, PJ; Huang, S; Joslyn, SK; LeBlanc, AK; Rao, J; Riggins, GJ; Rossmeisl, JH; Tonogai, EJ; Zhang, X, 2021) |
| "The diagnosis of an anaplastic oligodendroglioma (WHO grade 3) was made on pathological examination." | 5.35 | Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide. ( Chaskis, C; Michotte, A; Neyns, B; Sadones, J; Veld, PI, 2009) |
| " After irradiation of the symptomatic sites, intrathecal liposomal Ara-C every 2-4 weeks was combined with temozolomide 100 mg/m(2) day 1-5/7." | 5.35 | Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. ( Buhk, JH; Hoffmann, AL; Strik, H, 2009) |
| "Based on our findings in two paediatric patients, temozolomide may be a useful agent in the management of progressive recurrent low grade spinal cord astrocytomas." | 5.12 | Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. ( Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF, 2006) |
| "A prospective Phase II study of temozolomide (TMZ) was conducted in 16 patients with refractory meningioma." | 5.11 | Temozolomide for treatment-resistant recurrent meningioma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2004) |
| " Cases from June 2006 through October 2016 were identified for patients receiving bevacizumab and temozolomide for locally advanced, recurrent or metastatic solitary fibrous tumour or hemangiopericytoma, which is sometimes used to describe tumours arising from the meninges." | 3.91 | Efficacy of bevacizumab and temozolomide therapy in locally advanced, recurrent, and metastatic malignant solitary fibrous tumour: A population-based analysis. ( de Lemos, ML; Kang, I; Schaff, K, 2019) |
| "The LMD source was breast cancer (53 %) and non-small-cell lung cancer (37 %)." | 2.77 | Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. ( Balañá, C; Bruna, J; Chacón, I; Gil, M; Langa, JM; Martín, M; Segura, PP, 2012) |
| "Temozolomide (TMZ) is a DNA alkylating agent that appears to have a radiosensitizing effect when used in combination with RT and may be worthwhile in meningioma treatment." | 1.72 | Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review. ( Belanger, K; Damek, D; Lillehei, KO; Ormond, DR; Ung, TH, 2022) |
| "Glioblastoma multiforme is one of the most common malignant types of tumor arising from the central nervous system known for its devastating intracranial progress and dismal prognosis." | 1.62 | FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis. ( Malik, D, 2021) |
| "High-grade meningioma is an aggressive type of brain cancer that is often recalcitrant to surgery and radiotherapy, leading to poor overall survival." | 1.62 | Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients. ( Basuli, F; Berry, MR; Botham, RC; Chen, Z; Daniel, GB; Fan, TM; Hergenrother, PJ; Huang, S; Joslyn, SK; LeBlanc, AK; Rao, J; Riggins, GJ; Rossmeisl, JH; Tonogai, EJ; Zhang, X, 2021) |
| "Compared with pilocytic astrocytoma, PMA is more aggressive, has a higher rate of local recurrence, and often disseminates to the leptomeninges." | 1.38 | Successful treatment of leptomeningeal gliomatosis of pilomyxoid astrocytoma after failed frontline chemotherapy. ( Bouffet, E; Maeda, M; Morioka, M; Sawamura, Y; Sugita, Y; Terasaki, M, 2012) |
| "Meningiomas are usually cured by surgical resection." | 1.35 | Methylation status of MGMT gene promoter in meningiomas. ( Cairncross, G; de Robles, P; Easaw, J; Forsyth, P; Hamilton, M; Kalra, S; Magliocco, T; McIntyre, J; Roldán, G, 2008) |
| "The diagnosis of an anaplastic oligodendroglioma (WHO grade 3) was made on pathological examination." | 1.35 | Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide. ( Chaskis, C; Michotte, A; Neyns, B; Sadones, J; Veld, PI, 2009) |
| " After irradiation of the symptomatic sites, intrathecal liposomal Ara-C every 2-4 weeks was combined with temozolomide 100 mg/m(2) day 1-5/7." | 1.35 | Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. ( Buhk, JH; Hoffmann, AL; Strik, H, 2009) |
| "Thus, we describe a malignant meningioma model system that will be useful for investigating the biology of meningiomas and for preclinical assessment of therapeutic agents." | 1.35 | An orthotopic skull base model of malignant meningioma. ( Baia, GS; Dinca, EB; James, CD; Kimura, ET; Lal, A; McDermott, MW; Ozawa, T; VandenBerg, SR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.50) | 18.2507 |
| 2000's | 15 (37.50) | 29.6817 |
| 2010's | 20 (50.00) | 24.3611 |
| 2020's | 4 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gonda, T | 1 |
| Wakabayashi, K | 1 |
| Haraguchi, K | 1 |
| Arai, Y | 1 |
| Oyama, H | 1 |
| Belanger, K | 1 |
| Ung, TH | 1 |
| Damek, D | 1 |
| Lillehei, KO | 1 |
| Ormond, DR | 1 |
| Malik, D | 1 |
| Tonogai, EJ | 1 |
| Huang, S | 1 |
| Botham, RC | 1 |
| Berry, MR | 1 |
| Joslyn, SK | 1 |
| Daniel, GB | 1 |
| Chen, Z | 1 |
| Rao, J | 1 |
| Zhang, X | 1 |
| Basuli, F | 1 |
| Rossmeisl, JH | 1 |
| Riggins, GJ | 1 |
| LeBlanc, AK | 1 |
| Fan, TM | 1 |
| Hergenrother, PJ | 1 |
| van der Vlist, A | 1 |
| Snijders, TJ | 1 |
| Stades, AME | 1 |
| Spliet, WGM | 1 |
| De Vos, FYFL | 1 |
| de Lemos, ML | 1 |
| Kang, I | 1 |
| Schaff, K | 1 |
| Schwartz, C | 1 |
| Romagna, A | 1 |
| Machegger, L | 1 |
| Weiss, L | 1 |
| Huemer, F | 1 |
| Fastner, G | 1 |
| Kleindienst, W | 1 |
| Weis, S | 1 |
| Greil, R | 1 |
| Winkler, PA | 1 |
| Autran, D | 1 |
| Barrie, M | 1 |
| Matta, M | 1 |
| Monserrat, C | 1 |
| Campello, C | 1 |
| Petrirena, G | 1 |
| Boucard, C | 1 |
| Padovani, L | 1 |
| Loundou, A | 1 |
| Appay, R | 1 |
| Graillon, T | 1 |
| Dufour, H | 1 |
| Figarella-Branger, D | 1 |
| Chinot, O | 1 |
| Tabouret, E | 1 |
| Aghajan, Y | 1 |
| Malicki, DM | 1 |
| Levy, ML | 1 |
| Crawford, JR | 1 |
| Grah, JJ | 1 |
| Katalinic, D | 1 |
| Stern-Padovan, R | 1 |
| Paladino, J | 1 |
| Santek, F | 1 |
| Juretic, A | 1 |
| Zarkovic, K | 1 |
| Plestina, S | 1 |
| Supe, M | 1 |
| Kuo, LT | 1 |
| Tsai, SY | 1 |
| Yang, CY | 1 |
| Lin, LW | 1 |
| Yamasaki, K | 1 |
| Yokogami, K | 1 |
| Ohta, H | 1 |
| Yamashita, S | 1 |
| Uehara, H | 1 |
| Sato, Y | 1 |
| Takeshima, H | 1 |
| Wilisch-Neumann, A | 1 |
| Pachow, D | 1 |
| Wallesch, M | 1 |
| Petermann, A | 1 |
| Böhmer, FD | 1 |
| Kirches, E | 1 |
| Mawrin, C | 1 |
| Kong, X | 1 |
| Wang, Y | 1 |
| Liu, S | 1 |
| Chen, K | 1 |
| Zhou, Q | 1 |
| Yan, C | 1 |
| He, H | 1 |
| Gao, J | 1 |
| Guan, J | 1 |
| Yang, Y | 1 |
| Li, Y | 1 |
| Xing, B | 1 |
| Wang, R | 1 |
| Ma, W | 1 |
| He, J | 1 |
| Liu, C | 1 |
| Wang, B | 1 |
| Li, N | 1 |
| Zuo, G | 1 |
| Gao, D | 1 |
| Pellerino, A | 1 |
| Soffietti, R | 2 |
| Rudà, R | 2 |
| Sahuc, P | 1 |
| Joubert, C | 1 |
| Nguyen, AT | 1 |
| Fouet, B | 1 |
| Wybrecht, D | 1 |
| Faivre, A | 1 |
| Alla, P | 1 |
| Dagain, A | 1 |
| de Robles, P | 1 |
| McIntyre, J | 1 |
| Kalra, S | 1 |
| Roldán, G | 1 |
| Cairncross, G | 1 |
| Forsyth, P | 1 |
| Magliocco, T | 1 |
| Hamilton, M | 1 |
| Easaw, J | 1 |
| Jicha, GA | 1 |
| Glantz, J | 1 |
| Clarke, MJ | 1 |
| Lehwald, LM | 1 |
| Russo, DP | 1 |
| Giannini, C | 1 |
| Wald, JT | 1 |
| Uhm, J | 1 |
| Kumar, N | 1 |
| Aksamit, AJ | 1 |
| Wetmore, CJ | 1 |
| Walker, JG | 1 |
| Subbiah, V | 1 |
| Wolff, JE | 1 |
| Michotte, A | 1 |
| Chaskis, C | 1 |
| Sadones, J | 1 |
| Veld, PI | 1 |
| Neyns, B | 1 |
| Passarin, MG | 1 |
| Moretto, G | 1 |
| Musso, AM | 1 |
| Ottaviani, S | 1 |
| Masotto, B | 1 |
| Ghimenton, C | 1 |
| Iuzzolino, P | 1 |
| Buffone, E | 1 |
| Vattemi, E | 1 |
| Pedersini, R | 1 |
| Hoffmann, AL | 1 |
| Buhk, JH | 1 |
| Strik, H | 1 |
| Zauderer, M | 1 |
| Krug, LM | 1 |
| Pietanza, MC | 1 |
| O'Rourke, D | 1 |
| Schaefer, N | 1 |
| Rasch, K | 1 |
| Moehlenbruch, M | 1 |
| Urbach, H | 1 |
| Stuplich, M | 1 |
| Blasius, E | 1 |
| Scheffler, B | 1 |
| Herrlinger, U | 1 |
| Glas, M | 1 |
| Hansen, N | 1 |
| Wittig, A | 1 |
| Hense, J | 1 |
| Kastrup, O | 1 |
| Gizewski, ER | 1 |
| Van de Nes, JA | 1 |
| Terasaki, M | 1 |
| Bouffet, E | 1 |
| Maeda, M | 1 |
| Sugita, Y | 1 |
| Sawamura, Y | 1 |
| Morioka, M | 1 |
| Segura, PP | 1 |
| Gil, M | 1 |
| Balañá, C | 1 |
| Chacón, I | 1 |
| Langa, JM | 1 |
| Martín, M | 1 |
| Bruna, J | 1 |
| Salmaggi, A | 1 |
| Silvani, A | 1 |
| Eoli, M | 1 |
| Lamperti, E | 1 |
| Boiardi, A | 1 |
| Chamberlain, MC | 1 |
| Tsao-Wei, DD | 1 |
| Groshen, S | 1 |
| Wong, ET | 1 |
| Franceschi, E | 1 |
| Cavallo, G | 1 |
| Scopece, L | 1 |
| Esposti, RD | 1 |
| Paioli, G | 1 |
| Paioli, A | 1 |
| Palmerini, E | 1 |
| Foschini, MP | 1 |
| Marliani, AF | 1 |
| Crinò, L | 1 |
| Koch, HJ | 1 |
| Roeber, S | 1 |
| Zimmermann, UW | 1 |
| Schäfer, C | 1 |
| Villarrubia, V | 1 |
| Kuchelmeister, K | 1 |
| Schachenmayr, W | 1 |
| Bogdahn, U | 1 |
| Steinbrecher, A | 1 |
| Chamoun, RB | 1 |
| Alaraj, AM | 1 |
| Al Kutoubi, AO | 1 |
| Abboud, MR | 1 |
| Haddad, GF | 1 |
| Enting, RH | 1 |
| van der Graaf, WT | 1 |
| Kros, JM | 1 |
| Heesters, M | 1 |
| Metzemaekers, J | 1 |
| den Dunnen, W | 1 |
| Ku, GY | 1 |
| Krol, G | 1 |
| Ilson, DH | 1 |
| Baia, GS | 1 |
| Dinca, EB | 1 |
| Ozawa, T | 1 |
| Kimura, ET | 1 |
| McDermott, MW | 1 |
| James, CD | 1 |
| VandenBerg, SR | 1 |
| Lal, A | 1 |
| Sampson, JH | 1 |
| Archer, GE | 1 |
| Villavicencio, AT | 1 |
| McLendon, RE | 1 |
| Friedman, AH | 1 |
| Bishop, WR | 1 |
| Bigner, DD | 1 |
| Friedman, HS | 1 |
| Rao, RD | 1 |
| Robins, HI | 1 |
| Mehta, MP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
1 review available for temozolomide and Meningeal Neoplasms
| Article | Year |
|---|---|
Glioblastoma Secondary to Meningioma: A Case Report and Literature Review.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glial Fibrillary Acidic Prote | 2017 |
4 trials available for temozolomide and Meningeal Neoplasms
| Article | Year |
|---|---|
Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Da | 2012 |
Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Magnetic Reso | 2002 |
Temozolomide for treatment-resistant recurrent meningioma.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dexamethasone; Disease P | 2004 |
Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Child; Dacarbazine; Disease Progression; | 2006 |
35 other studies available for temozolomide and Meningeal Neoplasms
| Article | Year |
|---|---|
[Primary leptomeningeal gliomatosis treated with temozolomide: a case report].
Topics: Adult; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meninges; Neoplasms, Neuroepit | 2021 |
Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.
Topics: Brain Neoplasms; Child; Humans; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Retrosp | 2022 |
FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis.
Topics: Adult; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Meningeal Neoplasms; P | 2021 |
Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
Topics: Animals; Apoptosis; Caspase 3; Cell Culture Techniques; Cell Line, Tumor; Dogs; Humans; Hydroxyurea; | 2021 |
Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Meningeal Neoplasms; Pituitary N | 2017 |
Efficacy of bevacizumab and temozolomide therapy in locally advanced, recurrent, and metastatic malignant solitary fibrous tumour: A population-based analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Hemangiopericytoma | 2019 |
Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunol | 2018 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Atypical anaplastic astrocytoma with unique molecular features and diffuse leptomeningeal spread in a child with long-term survival.
Topics: Astrocytoma; Brain; Chemoradiotherapy; Child; Gene Amplification; High-Throughput Nucleotide Sequenc | 2019 |
Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality T | 2013 |
Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2017 |
Case of primary diffuse leptomeningeal gliomatosis.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Fat | 2014 |
Re-evaluation of cytostatic therapies for meningiomas in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification M | 2014 |
Brain Stem and Entire Spinal Leptomeningeal Dissemination of Supratentorial Glioblastoma Multiforme in a Patient during Postoperative Radiochemotherapy: Case Report and Review of the Literatures.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem Neoplasms; Chemoradiotherapy; Cisplatin; D | 2015 |
HMGN5 blockade by siRNA enhances apoptosis, suppresses invasion and increases chemosensitivity to temozolomide in meningiomas.
Topics: Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Dacarbazine; Drug Resistance, Neoplasm; F | 2015 |
Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Meningeal | 2016 |
Methylation status of MGMT gene promoter in meningiomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Modification Methy | 2008 |
Primary diffuse leptomeningeal gliomatosis.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain; Dacarbazine; Diagnosis, Differential; Humans; | 2009 |
Diagnosis and management of leptomeningeal disease.
Topics: Adult; Antineoplastic Agents, Alkylating; Benzenesulfonates; Dacarbazine; Female; Humans; Meningeal | 2009 |
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamid | 2010 |
Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Arachnoid; Brain; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2009 |
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytar | 2010 |
Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined M | 2009 |
Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lung Neoplasms; Mal | 2010 |
Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dacarbazine; | 2011 |
Long survival of primary diffuse leptomeningeal gliomatosis following radiotherapy and temozolomide: case report and literature review.
Topics: Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Humans; Male; Meningeal Neoplasms | 2011 |
Successful treatment of leptomeningeal gliomatosis of pilomyxoid astrocytoma after failed frontline chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Child, Preschool; Combined Modality Therapy; Cranial | 2012 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2005 |
Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Im | 2005 |
[Spinal and cerebral leptomeningeal seeding from a melanocytoma of the cerebello-pontine angle].
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Arachnoid; Cerebellar Diseases; Cere | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for leptomeningeal pilomyxoid astrocytoma: a case study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Cerebral Ventricle Neoplasms; Chemotherapy, A | 2006 |
Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
An orthotopic skull base model of malignant meningioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; D | 2008 |
Treatment of neoplastic meningitis with intrathecal temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Screening Assays, Antitumor; Humans; M | 1999 |
Late recurrence of a primitive neuro-ectodermal tumor.
Topics: Adult; Alkaline Phosphatase; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cerebellar Neopla | 2001 |